Biotech News
Related news
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
CUECue Biopharma Inc2026-08-03 12:30 EST
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
VERAVera Therapeutics2026-07-09 12:00 EST
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
KYTXKyverna Therapeutics2026-06-22 12:00 EST
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
TLSATiziana Life Sciences2026-08-06 11:00 EST
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
CUECue Biopharma Inc2026-07-13 12:30 EST
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
XFORX4 Pharmaceuticals2026-07-01 11:00 EST
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
SABSSAB Biotherapeutics2026-08-06 11:30 EST
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
INMBINmune Bio2026-07-31 11:00 EST
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-05-13 11:30 EST
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
ZURAZura Bio2026-05-07 11:30 EST
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-05-04 20:05 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 5.71 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States